BRPI0408274A - compostos de ligação de amilóide, composição farmacêutica e método de detecção de depósito de amilóide in vivo - Google Patents

compostos de ligação de amilóide, composição farmacêutica e método de detecção de depósito de amilóide in vivo

Info

Publication number
BRPI0408274A
BRPI0408274A BRPI0408274-5A BRPI0408274A BRPI0408274A BR PI0408274 A BRPI0408274 A BR PI0408274A BR PI0408274 A BRPI0408274 A BR PI0408274A BR PI0408274 A BRPI0408274 A BR PI0408274A
Authority
BR
Brazil
Prior art keywords
amyloid
compounds
pharmaceutical composition
detection method
vivo
Prior art date
Application number
BRPI0408274-5A
Other languages
English (en)
Inventor
William E Klunk
Chester A Mathis Jr
Yanming Wang
Original Assignee
Univ Pittsburgh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US10/388,173 external-priority patent/US7270800B2/en
Priority claimed from US10/645,847 external-priority patent/US20050043523A1/en
Application filed by Univ Pittsburgh filed Critical Univ Pittsburgh
Priority claimed from PCT/US2004/007797 external-priority patent/WO2004083195A1/en
Publication of BRPI0408274A publication Critical patent/BRPI0408274A/pt
Publication of BRPI0408274B1 publication Critical patent/BRPI0408274B1/pt
Publication of BRPI0408274B8 publication Critical patent/BRPI0408274B8/pt

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • G01N33/6896—Neurological disorders, e.g. Alzheimer's disease
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/60—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings condensed with carbocyclic rings or ring systems
    • C07D277/62—Benzothiazoles
    • C07D277/64—Benzothiazoles with only hydrocarbon or substituted hydrocarbon radicals attached in position 2
    • C07D277/66—Benzothiazoles with only hydrocarbon or substituted hydrocarbon radicals attached in position 2 with aromatic rings or ring systems directly attached in position 2
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/58—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving labelled substances
    • G01N33/60—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving labelled substances involving radioactive labelled substances

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Cell Biology (AREA)
  • Food Science & Technology (AREA)
  • Biotechnology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Microbiology (AREA)
  • Pathology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Magnetic Resonance Imaging Apparatus (AREA)
  • Thiazole And Isothizaole Compounds (AREA)

Abstract

"COMPOSTO DE LIGAçãO DE AMILóIDE, COMPOSIçãO FARMACêUTICA E MéTODO DE DETECçãO DE DEPóSITO DE AMILóIDE IN VIVO". A invenção proporciona compostos derivados do benzotiazol, composições que compreendem esses compostos, métodos de preparação desses compostos e métodos de uso desses compostos para detectar depósito(s) de amilóides e para diagnose de uma doença, desordem ou condição caracterizada por depósito(s) de amilóides. Os compostos encontram uso particular no diagnóstico e tratamento de pacientes com doenças onde a acumulação de placas neuríticas é prevalente. Os estados doentios ou doenças incluem, mas, sem limitação, a doença de Alzheimer, a doença familiar de Alzheimer, a síndrome de Down e homozigotos para o alelo E4 da apolipoproteína.
BRPI0408274A 2003-03-14 2004-03-15 compostos de ligação de amiloide e composição farmacêutica BRPI0408274B8 (pt)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US10/388,173 US7270800B2 (en) 2000-08-24 2003-03-14 Thioflavin derivatives for use in antemortem diagnosis of Alzheimer's disease and in vivo imaging and prevention of amyloid deposition
US10/388,173 2003-03-14
US10/645,847 US20050043523A1 (en) 2003-08-22 2003-08-22 Benzothiazole derivative compounds, compositions and uses
US10/645,847 2003-08-22
PCT/US2004/007797 WO2004083195A1 (en) 2003-03-14 2004-03-15 Benzothiazole derivative compounds, compositions and uses

Publications (3)

Publication Number Publication Date
BRPI0408274A true BRPI0408274A (pt) 2006-03-21
BRPI0408274B1 BRPI0408274B1 (pt) 2019-02-26
BRPI0408274B8 BRPI0408274B8 (pt) 2021-05-25

Family

ID=35057877

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0408274A BRPI0408274B8 (pt) 2003-03-14 2004-03-15 compostos de ligação de amiloide e composição farmacêutica

Country Status (16)

Country Link
EP (1) EP1611115B1 (pt)
JP (1) JP4875487B2 (pt)
CN (2) CN1784392A (pt)
AU (2) AU2004221897B2 (pt)
BE (1) BE2015C005I2 (pt)
BR (1) BRPI0408274B8 (pt)
CY (2) CY1113334T1 (pt)
DK (1) DK1611115T3 (pt)
ES (1) ES2393921T3 (pt)
FR (1) FR15C0005I2 (pt)
HU (1) HUS1500006I1 (pt)
NO (3) NO330861B1 (pt)
PL (1) PL1611115T3 (pt)
PT (1) PT1611115E (pt)
RU (1) RU2440995C2 (pt)
SI (1) SI1611115T1 (pt)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7270800B2 (en) 2000-08-24 2007-09-18 University Of Pittsburgh Thioflavin derivatives for use in antemortem diagnosis of Alzheimer's disease and in vivo imaging and prevention of amyloid deposition
DK1334091T3 (da) * 2000-08-24 2012-10-15 Univ Pittsburgh Thioflavinderivater og deres anvendelse til diagnose og terapi af Alzheimer's sygdom
JP2007538103A (ja) * 2004-05-20 2007-12-27 ザ スクリップス リサーチ インスティテュート トランスサイレチン安定化
GB0516564D0 (en) * 2005-08-12 2005-09-21 Ge Healthcare Ltd Fluorination process
ES2414614T3 (es) * 2007-01-30 2013-07-22 Ge Healthcare Limited Herramientas para ayudar en el diagnóstico de enfermedades neurodegenerativas
CN101293878B (zh) * 2007-04-25 2010-12-15 中国科学院上海应用物理研究所 苯并噻唑苯胺类化合物及其制备方法和应用
EP2323697A2 (en) * 2008-07-24 2011-05-25 Siemens Medical Solutions USA, Inc. Imaging agents useful for identifying ad pathology
DK2338059T3 (en) * 2008-09-23 2015-06-15 Wista Lab Ltd Ligands for aggregated tau molecules
WO2015044095A1 (en) * 2013-09-26 2015-04-02 F. Hoffmann-La Roche Ag Imidazo[1,2-a]pyridin-7-amines as imaging tools
JP6260967B2 (ja) * 2013-11-06 2018-01-17 国立大学法人京都大学 放射性ヨウ素標識化合物、及び、これを含む放射性医薬
CN103613589B (zh) * 2013-11-29 2016-03-30 江苏华益科技有限公司 一种用于神经退行性疾病领域的新型pet显像剂前体及标准品的合成方法
CA2959505A1 (en) * 2014-08-29 2016-03-03 Chdi Foundation, Inc. Probes for imaging huntingtin protein
CN109400615B (zh) * 2017-08-18 2021-07-16 上海交通大学医学院附属新华医院 一种靶向β-淀粉样蛋白的香豆素类化合物及其制备与应用
GR1009516B (el) * 2018-03-22 2019-05-02 Εκεφε Δημοκριτος Τρικαρβονυλο-συμπλοκα μεταλλων μεταπτωσεως με βενζο-ετεροκυκλικο παραγωγο του κυκλοπενταδιενυλικου ανιοντος με υψηλη διαπερατοτητα του αιματοεγκεφαλικου φραγμου για εφαρμογες στη διαγνωση και θεραπεια νοσων του κνς
CN119462558B (zh) * 2024-10-18 2025-09-19 河南中医药大学 一种布美他尼衍生物及其制备方法和用途

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HUP0001383A3 (en) * 1996-11-22 2001-11-28 Lilly Co Eli N-(aryl/heteroaryl) amino acid derivatives, pharmaceutical compositions comprising same and their use
GB9919673D0 (en) * 1999-08-20 1999-10-20 Cancer Res Campaign Tech 2-Arlybenzazole compounds
DK1334091T3 (da) * 2000-08-24 2012-10-15 Univ Pittsburgh Thioflavinderivater og deres anvendelse til diagnose og terapi af Alzheimer's sygdom
JP2004524289A (ja) * 2000-12-22 2004-08-12 アストラゼネカ・アクチエボラーグ 治療化合物
ES2274973T3 (es) * 2001-04-23 2007-06-01 The Trustees Of The University Of Pennsylvania Inhibidores de la agregacion de placas amiloides y agentes de obtencion de imagenes diagnosticas.
GB0229686D0 (en) * 2002-12-20 2003-01-29 Amersham Plc Solid-phase fluorination of benzothiazoles

Also Published As

Publication number Publication date
AU2004221897B2 (en) 2010-11-18
NO20054674D0 (no) 2005-10-11
BE2015C005I2 (pt) 2023-03-07
EP1611115A1 (en) 2006-01-04
NO2015005I2 (no) 2015-02-18
AU2004221897A9 (en) 2009-08-20
NO20110980L (no) 2005-12-13
HK1086270A1 (en) 2006-09-15
HUS1500006I1 (hu) 2015-02-18
RU2005131872A (ru) 2006-02-27
NO330861B1 (no) 2011-08-01
CN1784392A (zh) 2006-06-07
CY1113334T1 (el) 2015-12-09
NO2015005I1 (no) 2015-03-02
AU2011200667A1 (en) 2011-03-10
AU2004221897A2 (en) 2004-09-30
CN102532055A (zh) 2012-07-04
RU2440995C2 (ru) 2012-01-27
NO20054674L (no) 2005-12-13
CN102532055B (zh) 2016-05-11
AU2011200667B2 (en) 2011-12-22
SI1611115T1 (sl) 2012-12-31
CY2015007I1 (el) 2015-12-09
ES2393921T3 (es) 2013-01-02
BRPI0408274B1 (pt) 2019-02-26
AU2004221897A1 (en) 2004-09-30
DK1611115T3 (da) 2012-11-26
BRPI0408274B8 (pt) 2021-05-25
PL1611115T3 (pl) 2013-01-31
FR15C0005I2 (fr) 2015-07-24
EP1611115B1 (en) 2012-08-22
JP2006522104A (ja) 2006-09-28
PT1611115E (pt) 2012-12-07
JP4875487B2 (ja) 2012-02-15

Similar Documents

Publication Publication Date Title
BRPI0113470B8 (pt) composto de ligação amilóide, composição farmacêutica e métodos de síntese de composto, de detecção in vivo de depósitos amilóides num indivíduo e em tecido humano ou animal, de quantificação de depósito amilóide em tecido de biópsia ou postmortem e de distinção de um cérebro de doença de alzheimer de um cérebro normal
Xu et al. Luteolin promotes long-term potentiation and improves cognitive functions in chronic cerebral hypoperfused rats
He et al. A novel melatonin agonist Neu-P11 facilitates memory performance and improves cognitive impairment in a rat model of Alzheimer'disease
Christie et al. Structural and functional disruption of vascular smooth muscle cells in a transgenic mouse model of amyloid angiopathy
BRPI0408274B8 (pt) compostos de ligação de amiloide e composição farmacêutica
Cui et al. Designer self-assemble peptides maximize the therapeutic benefits of neural stem cell transplantation for Alzheimer’s disease via enhancing neuron differentiation and paracrine action
Ballesteros-Alvarez et al. Urolithin A reduces amyloid-beta load and improves cognitive deficits uncorrelated with plaque burden in a mouse model of Alzheimer’s disease
WO2008118122A3 (en) Compounds and amyloid probes thereof for therapeutic and imaging uses
BR0210391A (pt) Composto, métodos de tratar um paciente que tenha ou de prevenir um paciente de contrair uma doença ou condição e de preparar um composto, e, uso de um composto
TW200736252A (en) Novel heteroaryl substituted benzothiazoles
Li et al. Icariin, a major constituent of flavonoids from Epimedium brevicornum, protects against cognitive deficits induced by chronic brain hypoperfusion via its anti-amyloidogenic effect in rats
BRPI0717697A2 (pt) composto, composição farmaceutica, uso do composto, método para tratar um paciente sofrendo de uma condição patológica ou uma doença e combinação de produtos
MX2009005279A (es) Derivados de n-(metil)-1h-pirazol-3-amina, n-(metil)-piridin-2-ami na y n-(metil)-tiazol-2-amina para el tratamiento de enfermedades asociadas con proteinas amiloides o tipo amiloide, tal como por ejemplo alzheimer.
BRPI0416796A (pt) compostos orgánicos
BRPI0918194A2 (pt) ''composto, composição farmacêutica, uso de um composto, método para tratar um indivíduo que sofre de uma condição patológica ou doença e produto de combinação
WO2009003147A1 (en) Methods and compositions for the treatment of neurological disorders
WO2010115843A3 (en) Pharmaceutical composition
BRPI0414565A (pt) composições farmacêuticas e métodos que compreendem combinações de derivados de 2-alquilideno-19-nor-vitamina d e um bisfosfonato
BRPI0609020A2 (pt) polipeptídeo, proteína de fusão, molécula de ácido nucleido purificada, vetor, célula hospedeira, ligando, composto, método para diagnosticar uma doença em um paciente, uso de um polipeptídeo, composição farmacêutica, composição de vacina, métodos para monitorar o tratamento terapêutico de doença em paciente e para a identificação de um composto que é eficaz no tratamento e/ou diagnóstico de doença, kit, animal não humano transgênico ou knockout, método para a triagem quanto a um composto eficaz para tratar doença, e, método para selecionar compostos biologicamente ativos"
Nasir Abbas Bukhari et al. Synthetic curcumin analogs as inhibitors of β-amyloid peptide aggregation: potential therapeutic and diagnostic agents for Alzheimer's disease
ATE470151T1 (de) Diagnose, behandlung und prävention von gefässerkrankungen mittels il-1alpha- autoantikörpern
DE602004016010D1 (de) Verfahren zur ä11cü-radiomarkierung von phenthiazin und phenothiazinartige verbindungen
WO2004064869A3 (en) Amyloid-binding, metal-chelating agents
WO2010051196A8 (en) Novel substituted azabenzoxazoles
Takeda et al. Elevation of plasma β-amyloid level by glucose loading in Alzheimer mouse models

Legal Events

Date Code Title Description
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B09A Decision: intention to grant [chapter 9.1 patent gazette]
B25D Requested change of name of applicant approved

Owner name: UNIVERSITY OF PITTSBURGH - OF THE COMMONWEALTH SYS

B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]

Free format text: PRAZO DE VALIDADE: 10 (DEZ) ANOS CONTADOS A PARTIR DE 26/02/2019, OBSERVADAS AS CONDICOES LEGAIS.

B25G Requested change of headquarter approved

Owner name: UNIVERSITY OF PITTSBURGH - OF THE COMMONWEALTH SYS

B16C Correction of notification of the grant [chapter 16.3 patent gazette]

Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 15/03/2004 OBSERVADAS AS CONDICOES LEGAIS. PATENTE CONCEDIDA CONFORME ADI 5.529/DF

B21F Lapse acc. art. 78, item iv - on non-payment of the annual fees in time

Free format text: REFERENTE A 22A ANUIDADE.

B21H Decision of lapse of a patent or of a certificate of addition of invention cancelled [chapter 21.8 patent gazette]

Free format text: ANULADA A PUBLICACAO CODIGO 21.6 NA RPI NO 2871 DE 13/01/2026 POR TER SIDO INDEVIDA.